

Resource Summary Report

Generated by [dkNET](#) on Sep 14, 2026

Hep 3B2.1-7

RRID:CVCL_0326

Type: Cell Line

Proper Citation

RRID:CVCL_0326

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0326

Proper Citation: RRID:CVCL_0326

Description: Cell line Hep 3B2.1-7 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood hepatocellular carcinoma

Defining Citation: [PMID:233137](#), [PMID:2439335](#), [PMID:3023526](#), [PMID:3431441](#), [PMID:6248960](#), [PMID:6275024](#), [PMID:6288577](#), [PMID:7972006](#), [PMID:8050184](#), [PMID:8224613](#), [PMID:8389256](#), [PMID:8835345](#), [PMID:9290701](#), [PMID:9359923](#), [PMID:10523694](#), [PMID:11050057](#), [PMID:12029633](#), [PMID:15767549](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:20937217](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:24116068](#), [PMID:25574106](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29610054](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:32899426](#), [PMID:34320349](#), [PMID:35839778](#)

Comments: Karyotypic information: Has lost chromosome Y., Population: African American., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Hep 3B2.1-7

Synonyms: Hep 3B2_1-7, Hep 3B 2.1-7, HEP3B217, Hep 3B2, HEP-3B2, HEP3B2, Hep-3B, HEP-3B, Hep 3B, Hep3B, HEP3B

Cross References: BTO:BTO_0000972, CLO:CLO_0003702, CLO:CLO_0003703, CLO:CLO_0003710, EFO:EFO_0002205, MCCL:MCC:0000221, CLDB:cl1627, CLDB:cl1628, CLDB:cl1629, CLDB:cl1630, AddexBio:C0015001/45, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HB-8064, BCRC:60434, BCRJ:0357, BioGRID_ORCS_Cell_line:810, BioSample:SAMN03473193, BioSample:SAMN10988098, cancercellines:CVCL_0326, CCRID:1101HUM-PUMC000376, CCRID:1101HUM-PUMC000474, CCRID:1102HUM-NIFDC00059, CCRID:3101HUMSCSP5045, CCRID:3101HUMTCHu106, CCRID:4201HUM-CCTCC00070, CCTCC:GDC0070, Cell_Model_Passport:SIDM00672, CGH-DB:454-3, CGH-DB:9069-4, ChEMBL-Cells:ChEMBL4106361, ChEMBL-Targets:ChEMBL4296437, CLS:305141, Cosmic:873401, Cosmic:928140, Cosmic:934549, Cosmic:948066, Cosmic:979729, Cosmic:999851, Cosmic:1019316, Cosmic:1177682, Cosmic:1351510, Cosmic:1518225, Cosmic:1628385, Cosmic:2023864, Cosmic:2162536, Cosmic:2301557, Cosmic:2321030, Cosmic:2668282, Cosmic:2773181, Cosmic:2816904, Cosmic-CLP:1240147, DepMap:ACH-000625, DSMZ:ACC-93, DSMZCellDive:ACC-93, ECACC:86062703, EGA:EGAS00001000978, GDSC:1240147, GEO:GSM207050, GEO:GSM501778, GEO:GSM565879, GEO:GSM887078, GEO:GSM888148, GEO:GSM936759, GEO:GSM1374531, GEO:GSM1669879, GEO:GSM2551564, Hysigen:TCH-C195, IARC_TP53:30036, IGRhCellID:Hep3B, IZSLER:BS TCL 78, KCB:KCB 200771YJ, KCB:KCB 200942YJ, KCLB:88064, LiGeA:CCLE_655, LIMORE:Hep3B, LINC_S_LDP:LCL-1924, Lonza:473, PharmacDB:Hep3B2_17_538_2019, PRIDE:PXD000533, PRIDE:PXD000535, PRIDE:PXD005291, PRIDE:PXD008190, PRIDE:PXD030304, Progenetix:CVCL_0326, PubChem_Cell_line:CVCL_0326, RCB:RCB2090, TKG:TKG 0291, TOKU-E:1439, TOKU-E:3574, Ubigen:YC-D002, Wikidata:Q54882746

ID: CVCL_0326

Record Creation Time: 20220427T220333+0000

Record Last Update: 20260913T004020+0000

Ratings and Alerts

No rating or validation information has been found for Hep 3B2.1-7.

Warning: Discontinued: RCB; RCB2090

Karyotypic information: Has lost chromosome Y., Population: African American., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4014 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Weiskirchen R, et al. (2026) Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review. *Medical sciences (Basel, Switzerland)*, 14(1).

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. *Cells*, 15(1).

Peng X, et al. (2026) Peroxisome-derived and liver-specific hydroxyacid oxidase 1-mediated hydrogen peroxide promotes ferroptosis by augmenting peroxisomal ROS. *Journal of advanced research*.

Xu M, et al. (2026) UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting β -Catenin-Driven Hybrid EMT and NK Cell Evasion. *Cancer research*, 86(13), 3213.

Li Z, et al. (2026) Bio-inspired fractal-structured gel-drugs enable enhancing deep tumor penetration for efficient chemotherapy of hepatocellular carcinoma. *Journal of controlled release : official journal of the Controlled Release Society*, 394, 114899.

Wang LT, et al. (2026) ISX-TWIST1 reprograms CD47-inflammasome signaling to reshape the immune microenvironment in liver cancer. *Experimental hematology & oncology*, 15(1).

Chen WT, et al. (2026) Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. *HGG advances*, 7(3), 100630.

Khanduja S, et al. (2026) Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory. *Cell reports. Medicine*, 7(6), 102839.

Zheleznyak A, et al. (2026) Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. *Cancer research communications*, 6(1), 178.

Li L, et al. (2026) USP25 aggravates liver cancer development and impairs chemosensitivity by limiting LATS1 activation. *EMBO reports*, 27(9), 2406.

Xing J, et al. (2026) Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes. *Cell*, 189(9), 2556.

Guo WW, et al. (2026) CCT2 Orchestrates Glycolysis and Exosome-Mediated M2 Macrophage Polarization in HCC tumorigenesis. *International journal of biological sciences*, 22(7), 3389.

An X, et al. (2026) MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma. *Frontiers in immunology*, 17, 1849407.

Luo Q, et al. (2026) ILF3 Regulates Cell Proliferation and Metastasis by Competitively Antagonizing the Interaction Between HMGCL and USP38 in Hepatocellular Carcinoma. Human mutation, 2026, 2654435.

Chen Z, et al. (2026) USP1 promotes hepatocellular carcinoma progression by modulating mitophagy via stabilizing MCM3 to regulate the Keap1-Nrf2 axis. iScience, 29(3), 114927.

Aita Y, et al. (2026) A functional SNP rs12718466 in APOA1 promoter modulates gene expression via interaction with SOX7. The Journal of biological chemistry, 302(6), 113101.

Lin Z, et al. (2026) Glypican-3-Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 550.

Lee J, et al. (2026) Dammarenediol II enhances etoposide-induced apoptosis by targeting O-GlcNAc transferase and Akt/GSK3 β /mTOR signaling in liver cancer. Molecular oncology, 20(6), 1591.

Guo Z, et al. (2026) RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic/epigenetic axis. Journal of translational medicine, 24(1).

Yu S, et al. (2026) Hepatic Stellate Cell-Specific METTL3 Deficiency Promotes Hepatocellular Carcinoma Progression via BMP10-SMAD1/5/8 Signaling. Cancer research communications, 6(5), 1109.